00791nas a2200277   4500000000100000000000100001008004100002653002400043653002800067653002000095653003800115653004000153653001200193653004600205100001400251700001900265700001400284700001100298700001500309700001500324245012600339250001500465300001100480490000800491020001400499       2022                            d10aAll-cause mortality10aCardiovascular outcomes10aEffect modifier10aHospitalization for heart failure10aMajor adverse cardiovascular events10aobesity10aSodium-glucose cotransporter-2 inhibitors1 aK. Suissa1 aS. Schneeweiss1 aA. Douros1 aH. Yin1 aE. Patorno1 aL. Azoulay00aObesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes  a2022/09/28  a1100940 v192  a0168-8227